These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Jones KL; Johnson KA; Dick LM; Felix RJ; Kao KK; Chambers CD Teratology; 2002 Mar; 65(3):125-30. PubMed ID: 11877776 [TBL] [Abstract][Full Text] [Related]
3. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087 [TBL] [Abstract][Full Text] [Related]
4. Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. De Santis M; Straface G; Cavaliere AF; Carducci B; Caruso A Drug Saf; 2006; 29(3):255-9. PubMed ID: 16524324 [TBL] [Abstract][Full Text] [Related]
7. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon? Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252 [TBL] [Abstract][Full Text] [Related]
8. Myocardial infarction induced by appetite suppressants in Malaysia. Azarisman SM; Magdi YA; Noorfaizan S; Oteh M N Engl J Med; 2007 Nov; 357(18):1873-4. PubMed ID: 17978302 [No Abstract] [Full Text] [Related]
10. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Perrio MJ; Wilton LV; Shakir SA Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225 [TBL] [Abstract][Full Text] [Related]
12. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL; N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901 [TBL] [Abstract][Full Text] [Related]
13. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K; J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224 [TBL] [Abstract][Full Text] [Related]
14. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure]. Astrup A Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391 [TBL] [Abstract][Full Text] [Related]